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Abstract
Patients with schizophrenia are typically treated with a neuroleptic and some form if
psychosocial intervention. In spite if optimum treatment, up to one-third ifpatients continue to
remain severely disabled due topersistent positiveornegativesymptoms. A varietyifdrugs have been
triedas alternativesor additions to traditional neuroleptics in thesepatients. This paperis a review
ifthese nonneuroleptic treatment alternatives and an attempt to establish someguidelines.for their
use.
The cur re nt approac h to treatm ent of patien ts wit h schizophreni a is a combina-
t ion of medi cation a nd psych osocial int ervention; this approach has yie lde d the best
res ults ( I). The efficacy of medi cation is well documented (2) , ye t up to 30% of
patients who have had opt im um tria ls of neu rol eptics continue to expe rience posit ive
or negative sym pto ms, or di spl ay un con trolled behavior (2) . Pa t ie nts wh o do not
respond ade quate ly to neuroleptics may be severe ly impai red du e to persisten t
sym pto ms . They may also develop significa nt side effects like ta rdive dyskinesia . It is,
th erefore, ext reme ly importa n t th a t alternat ive therapies be developed to br ing
th ese sym pto ms under con trol. Seve ra l t rials invo lving non neurolept ic agents ha ve
been carried out with va rying results. Can these resu lts be exte nde d to involve all
neuroleptic resist ant patients? How does one decid e which pa tien t to match with
whi ch drug? This paper is a n a t te m pt to t ry to answer these q uest ions and also to
review th e th erap eutic modalities avail abl e for th e neu roleptic resis tant pa tient.
Kane et al (3) defin ed neuroleptic resist ance as occurring in a patient who
cont inued to expe rie nce significan t impairment fro m sympto ms of the illn ess in spite
of trials of at least 3 different neuroleptics, from 2 di fferent chemica l cla sses, for six
weeks each, in doses of up to 1,500 mgs of chlorpro maz ine eq uiva lent, over th e last 5
yea rs, a fte r organi c pathology had been rul ed ou t. This defini tion of resist ance
appears to be com pre he nsive and is wid ely used . Sho uld blood levels be a part of th e
definition of resistance? At this stage, testing for blood levels of neuroleptics is not
routinely us ed in clinical se t t ings because both actual resul ts a nd test ing techniques
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have not been cons iste n t. Future definiti on s of neu rolep t ic resistance may well
include blood level cr ite ria.
The term neuroleptic origina te d fro m "neuroleptanalgesia"-a form of sho rt
ac t ing a nesthesia combin ing a n opia te deriva tive, fentanyl, and an antipsych ot ic,
drop eridol (4) . The term has since come to refer to a n ag ent that ha s both an
a n t ipsycho t ic effec t a nd a n ex t ra pyra m idal side effect profile (EPS). This review
focu ses on drugs that a re not st r ictly neuroleptics-sp ecifically, drugs that have been
shown to have an tipsychot ic effec t, but no significan t EPS profile .
Lithium
Studies have shown that adding lithium to a neuroleptic ca n help treatment
resist ant patients. We look ed a t seve ra l whi ch were eithe r important reviews (5) , or
stud ies th at have used RD C crite r ia (6) and sing le blind (7) or double blind designs
(8,9) with crossove r ph as es using placebo , for a total of a t least four wee ks each. The
usu al se ru m levels of lithium in th ese trials have ran ged from 0.9-1.2 me qs / liter and
th ey have lasted from 3-5 wee ks. Improvement in patients was docu men ted in th e
following areas: psychotic sym pto ms , coo pe ra t ion, social compe te nce, neatness,
irritability, a nd excite me n t (9) . Lithium a lone was in feri or to ne uroleptics in th e
ac u te ly ill patient, th ou gh it is useful as an adj unc t in schizophrenia or schizoaffective
d isorde r (5,9) . Affective sym pto ms need not be present for im provement to occur,
th ou gh pr esen ce of a ffect ive sym pto ms may pred ict a bett er response to treatment
wi th lithium. Respon se to lith ium does not mean a ne ed to cha nge th e diagnosis to a
mood di sorder. Lithiu m may decrease chronic symptoms and ma y decr ea se th e ra te
of relapse by as mu ch as 30% in schizoaffective illness (8) . There were a few ea rly
reports of a reversibl e delirium wh en lithiu m was combined with high do ses of
neuroleptics ( 10). These have been shown to be com plete ly revers ible when th e drug
was discontinued a nd now appear to have been cases of neuroleptic malignant
syndrome.
In conclus ion, adding lithium to neuroleptics in treatmen t res istant patient s ca n
result in decr eas ed psych oti c sym pto ms, excite me n t, irritabili ty and possibly ra tes of
relapse . Pr esen ce of affective sym pto ms appears to pr edi ct bett er res ponse in th ese
patients.
Beneodiazepines
Our review of th e lit erature reveal ed 15 double-blind stud ies of th e use of
benzodiazepines in schizophrenia. Only four (11-1 4) us ed DSM-III (15) a nd /or RDC
crite r ia for diagnosis, had double-blind desi gn s with placeb o crossove rs and last ed
from 2-8 weeks . Typicall y benzodiaz epines a re used in conj unc t ion with ne urolept ics,
and stud ies have shown decr eased hostility, ten sion , exc ite me nt, an d incr eased
spontaneous soc ia l engageme nt (11 ,1 2). Sp ecific benzodi azepines studied include
alprazola m (12, 14), di az ep am , chlord iazepoxide (13,14), a nd estazolam ( I I). Lon ger
ac ting drugs like di az ep am a nd chlord iazepo xide a re sa fe r, as they generally have
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milder withdrawal sym ptoms. Benzod iazepines have usu all y been used d uring exace r-
bations of psychosis to decreas e agita t ion . Benzod iazepines must be used ca refully
d ue to the po ten tial problems of abuse, withdraw a l sym ptoms incl uding sei zu res a nd
occa siona l soci a l d isin hibi tion.
In add it ion to clinica lly available benzodiazepines, GABA mimetic age nts an d
pa rtial ben zodiazepine agonists have a lso been stud ied expe r im entally. In theory,
thes e agen ts shou ld prod uc e a nxiolyt ic and anticonvulsant effec ts wi th out th e
seda t ive and muscle re laxan t effec ts of benzodiaz epines . It is a lso a n t icipa te d that
they mi ght produce d ecreas ed C NS depressant ac t ivity with red uced toxi city in th e
ove rdose situa t ion, lack of potentiat ion of alcoho l effec ts, and red uced ph ysica l
d ependence and abus e liability. Mu scimol , a GABA mimetic, was found to aggrava te
psych otic sym ptoms, whi le others, including tet rahydroisox azolop yr id inol, gamma-
acetylenic GABA, gam m a vin yl GA BA, and progabide, have been show n to produce
no effec t in sc hizo phrenia . Pa r t ial agonist s, including abccarnil , a lpidc rn, d ivalon , an d
bret az en il, have be en st udied , wi th on ly bretaz eni l (up to 4.5 mgs/day) producing an y
effec t. It produced a 40 % decrease in BPRS scores, effect s on bot h positi ve a nd
nega tive symptoms, no EPS and mild seda t ion when give n to 11 6 pa ti ent s for 3 weeks
(26) . Benzodiazepines have also proved useful in treating so m e of th e side effects of
neuroleptics like akathisia, tardive dyskinesia, and dyst onia (2). U nfortuna te ly, most
stud ies of th e us e of benzodiazepines in patients with sc hizo phre nia have used ve ry
sm a ll sa m ple siz es, thus lim iting th e conclus ions th at ca n be drawn fro m th em.
In conclusio n, benzodiazepines ca n be effect ive in treating ce rt a in neuroleptic
sid e effec ts, and th ey may a lso have a ro le to play wh en com bined with neu rol ept ics in
patients who display anx iety, psychosis, or agitation not resp onding to conve n t ional
neurolep tics a lon e. GA BA mim etics and partial benzodiaz epine agon ists have not
cons istent ly been show n to be effec t ive in studies to date . However , th e one
encou raging re por t on bre tazen il a nd th e m uch bett er side effec t profile of th e group
in gen eral make furth er research in this a re a imperative.
Carbamaeepine
Tria ls with ca rba m aze pine in schizop hrenia a re fairly new a nd the drug is
typi ca lly us ed in add it ion to neuroleptics. Of 5 double-blind stud ies of th e use of
ca rba maze pine in patien ts with sc hizophre n ia, three a re su pe r ior, uti lizin g OSM-III
or RO C cr ite r ia for the diagnosis of sc hizop hre nia , the crossove r forma t with pla cebo,
standard rating sca les, a nd serum ca rba m aze pine level s between 5- 18 mcgs/ml
(16-18). T r ial s have lasted 4-6 weeks. In neuroleptic refractory patients, ca rba m-
azepine has been shown to decreas e excite me nt, mania lik e sym p toms , suspi cious-
ness , violen ce , and aggression . C arbamazepine has a lso been shown to be useful in
nonepi leptic schizophrenic patients with tempora l lob e EEG abno rmalit ies, wit h suc h
pat ients showing decreased aggressive act s a nd improved se lf-con t ro l in int erpe r-
sonal situa t ions ( 17).
These studies see m to suggest that any effect of ca rba mazepine on psych ot ic
symptoms is modest. The main ben efit of ca rba m aze pine in patients with schizoph re-
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nia may be in decr easing aggress ion, ove rac t ivity, a nd improving cont ro l in int erper-
son al situa tions .
Propranolol
Initial trials of propranolol in schizophreni a were received with enthus iasm,
how ever lat er work has not been as encourag ing. Pr opran olol has been used in
com bina tion with neurolcptics, initially th e ra cemic (d-I) form and lat er the dextro
(d) form, both of whi ch a ppear to have so me a nt ipsycho t ic ac t ion (19-2 1). Doses have
va ried from 1000-3000 mgs per day; th ese do ses a re high eno ug h to leave th e patient
a t risk for se rious ca rd iovasc ula r or respirat ory side effec ts. O f 9 double-blind stud ies
ava ilable, th e three cite d used 35 or mor e patients, mad e di agnoses on th e Present
State Examination (PSE) (22) and used mor e th an one standard ra ting scale for
follow-up. Propranolol has been shown to incr ease blood levels of chlor promazine and
thioridazine, but not haloperidol, and to have a ben eficial effec t on a ka thisia (20).
Some authors have postulated th ese as th e mechanisms of ac t ion, instead of a
primary an tipsycho t ic effec t (2) .
These stud ies sugges t th at an y a nt ipsycho tic effec t of propran olol is a t best sligh t
and may be relat ed to it s ben eficial ph armacokinetic int eract ion s or to a de cr ease in
aka th isia. This, a long with it s side effec t pro file, make it a limi ted adj unct for patien ts
with treatment resist ant sch izophre nia .
Clozapine and Other Novel Antipsychotic Drugs
Cl ozapine first a ppe a re d in th e 1970's in Europe as a n an ti psycho t ic st ruct urally
relat ed to loxapine and effec t ive in a subgroup of treatment resist ant pat ient s. It
th en disappeared for severa l years following seve ra l report s of ag ra nulocytosis
occurring with th e drug, but ha s recently eme rged ag ain following severa l ca re fu lly
cond uc ted studies (2,3,23- 26). Up to 30% of treatment resist ant pat ients have shown
subs tant ia l improvement in positive an d negative sym ptoms an d on global rating
sca les wh en given clozapine in doses ran gin g from 300-600 mgs pe r day for up to 6
wee ks. The drug see ms to have mesolimbic a nd cor t ica l spec ificity, th erefore it is
assoc ia te d with a very low incid en ce of Parkinsoni an sym pto ms a nd tardive dys kin e-
sia . It a ppe a rs to act by influ en cin g multiple neurotran smitt er sys te ms . It has an
a n t icho line rgic and antihistaminic effec t, is a n a n tagonist a t 5HT2 a nd 5HT3
receptors, has an antiadrenergic action, a D I and D3 a long with some D2 blockin g
action at dopamine receptors and also increases dopamine release in th e mesocor t i-
cal syste m . Its effect on 5HT2 a nd 5HT3 receptors a nd it s ability to incr eas e
dopamine releas e in th e meso cortical syste ms may underlie it s effects on nega t ive
sys te ms . A major side effec t includes agranulocytosis, whi ch was ini tially see n in up to
13% of patients, a nd whi ch is now believed to occur in abo ut 1.6% of pat ients on th e
drug for more th an on e year. This effec t is reversibl e if th e drug is discont inued.
Weekl y white blood ce ll coun ts are advised a nd th e maximum risk peri od is bel ieved
to be between 6 weeks and 6 months. Other side effec ts include se izures in dos es
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gre a te r th an 600 mgs per day, hypertension a nd sia lorrhea, the last two bein g
at ypical for an agent with antiadrenergic a nd an t icho linergic action.
An tidepressants
" De pression" in schizophre nia is com mo n with up to 50% of first episode
patien ts and 30% of chronic patients meeting crite ria for major depression a nd 10%
of schizophrenics dying of su icide (27). However , wh at constitu tes "depression" in
schizophrenics ca n be difficult to assess as organic factors , includi ng a ne mias ,
ca nce rs, endocrine a nd neurological di sorders a nd medi cat ions, negative symptom s,
drug induced a kines ia and ak athisia, cog nit ive cha nges a nd pa rt ia l insight int o th e
nature and conse q ue nces of th e illn ess are a ll ca pa ble of mim icking depression .
Depression may also be prominent in th e prod rome of psychot ic relapse and in
schizoaffective dis order. Tw o major ar t icles have reviewe d th e ro le of antidepressants
(tricyclics, MAO inhibitors a nd possibly lithium) in schizop hrenia (27,28). Furth er,
Siris (29) has very recently reviewed th e assessme n t a nd treatment of depressi on in
schizo phre nia. These reviews sugges t th at a nt idepressan ts have a role in th e treat-
ment of depression in schizophre nia a fte r th e confoundi ng factors mentioned have
been rul ed ou t.
Antidepressants have pr oduced better res ults in outpatients ra th er th an in
inpat ients a nd in patients who are not ac t ively psychotic. Most st udi es have used
doses com pa ra ble to those used in pr im a ry depression, and t rials have lasted a t lea st
six week s. Dir ect com pa risons of di fferent tricyclic a nt ide pressants or of tri cyclics
with othe r antidepressants have not been repor ted. Siris (29) recommends th at th e
dose of th e a n t ide pressa nt be gradually incr eased a nd th at th ey be used in com bina-
tion with ong oing neuroleptic and a n tiparkinso nia n t reat men t. Long-ter m maint e-
nance treatment may be ben eficial for th e patient who responds favorably init iall y.
Antidepressants have not been shown to be effec t ive for nega tive symptoms. Most
re po rted double blind placebo con tro lled tria ls have invo lved t ricyclic antidepres-
sa n ts . H owever, sca t te red pr elimina ry rep orts sugges t t hat monoamine oxidase
inhibitors a nd se lec t ive seroto nin reupt ak e inh ibit or s may be effective as well (29) . It
sho uld be not ed th at wh en t ricyclics are used with an t ipsychot ics, the blood levels of
both d rugs ca n incre ase as ca n th e a ntic ho line rgic effect. T herefore , an y improve-
ment noted may be spurious.
L-Dopa and Reserpine
Our review reveal ed four stud ies assessing th e ro le of L-dopa in schizophreni a ,
mo st of whi ch wer e ca rr ied ou t in th e 1970's a nd in which pa tients were diagnosed
without using standard ized criteria . A fur th er limitation is that follow-up has been
based on a globa l clinical impression a nd not standardized ra t ing scales. Trials have
us ed dos es between 300- 2000 mgs per day for 6- 8 wee ks, usually com bined with
neuroleptics and a peripheral dop ad ecarboxyla se inhibitor. Stud ies (2,30) sugge st
that chro nic patients with negative sym pto ms, usuall y hospital ized a nd refra ctory to
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treatment, ca n show some incr eased ac t ivity, a le r t ness, socia l con tact a nd motiva-
tion. Sid e effects of L-Dopa in this population significantly limit it s use. T hese include
worsening of psychotic sym ptoms , agitation, and drug-induced dysk inesias. More
research is ne eded as L-Dopa may be useful in patients with negat ive sym ptoms, and
this subgroup has proved refractory to most drug trials.
Reserpine (2,31) was the first drug to prove effec t ive in treating patien ts with
psychosis and was wid ely used prior to th e introduction of neuroleptics in the 1950's .
Our review of th e lit erature rev ealed a total of 8 studies asse ssing th e effectiveness of
reserpine in schizophrenia. The best of th ese (3 1) used a tot al of 120 patients, lasted 6
months and com pa red reserpine 2 mgs/day versus chlorpro maz ine 200 mgs/day and
placebo. In doses of 2-12 mgs per da y for up to 6 weeks, patients have shown modest
improvement in positive symptoms and inte rpe rso nal functioni ng. Signi ficant side
effec ts of reserpine include depression , hypotension, and exace rba t ions of asthma
and peptic ulcer. Sin ce both reserpine and antipsych oti cs ac t by decreasing DA
transmission, it may not be effective in neuroleptic resistant patients. The major
limitation here is th e lack of recent lit erature and th e side effec ts of th e drug which
limit it s us efulness in schizophrenia.
Other Non-Neuroleptic Drugs
Man y othe r agen ts have been tri ed as alte rna tive treatmen ts in neuroleptic
resist ant schizo phre nics. For man y like ba clofen (32), bet aen dorphi n (33) , calcium
cha nne l antagonists (34), cho lecys to kinin-like agents (35), megavit amins (36), bromo-
cript ine (37) , a pomorphine (38) , naloxone and naltrexon e (39,40), and thyrotropin
releasing hormone (41) , th e majority of con t ro lled studies have not doc umen ted
sustained efficacy. For others like valproate (42) , vasopressin (43), a nd clonid ine (44),
eithe r double blind data are too pr eliminary, or sid e effec ts like postural hypot en sion
or fluid ret ention do not allow even pr eliminary conclus ions .
Conclusions
Our review of th e lit erature sugges ts that th e best way to man age th e t rea t ment
resistant schizophre nic is to identify th e persisting sym ptoms a nd th en apply various
treatment options. For patients with persisting positive sym pto ms, drugs to be
conside re d include clozapine, lit hium , benzodiaz epines a nd ca rba mazepine. For
patients with mainly negative symptoms, drugs to be conside re d include cloza pine
and alprazolam. If pa t ie nts display pr edominant aggression and poor impulse cont ro l
secondary to positive symptoms, treat with drugs shown useful for positive sym pto ms.
If aggression and poor impulse con t ro l occurs ind ependently, drugs th at ca n be used
include ca rba maze pine, beta blockers, lithium, and possibl y sero to ne rg ic agen ts in
light of evide nce linking se rotonin dysfunction with violence a nd aggression. It is best
to avoid benzodiazepines in this group as th ey ca n lead to disinhibited be havior.
Figure I below summarizes the rol e of non-neuroleptic pharmacotherap y in neuro-
leptic resistant schizophrenic patients.
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I Define sch izop hrenia using standardized criteria such as DSM-III-R I
I
I Ad equate trial of neuroleptics I
I
Resistan ce-s-d efi ne using com pre he ns ive cri ter ia ,
su ch as Kane e t a l (3)
->:
Idcntify side-effects a nd tes t : Consider EEG: trial of
I. Parkinsonism - antich olincrgics (t re mor ); ca rba mazc pinc
am an tad ine (rigid ity and a kinesia)
/2. Akath isia-ben zodi zapincs or bet a blockers3. Tardive dyskinesia- adj ust dos e ofan ti psychotics/ant icho linergics,bcn zodi azepines, te t rab en azin e, e tc .
~/
Sym ptoms persist ing- idcn t ify spec ific ta rget sympto ms a nd add one of thc drugs
below, a lways combining with psychosocial th crap y.
~~
Positive Negative Violence or Depression
Symptoms Symptoms Agression Tri al of ECT,
Trial of Trial of clozapinc, Tria l of ca rba- followed by
lithium, ECT, 5lIT antagonists. mazin e, li th iu m, an tid epressants, if
cloza pine, in tha t Also conside r be ta blockers, and nccd cd . Rule ou t
ordc r. a lprazola m . 5HT agonists nega t ive
Also co ns ide r symptom s,
ca rba mazepine cognitive cha nges,
a nd EPS a nd rcacti vc
ben zodiazep ines. depression
FIGURE 1. Flow sheet for neuroleptic resistant schizophrenic patients .
NON-NEU RO LEPTIC PHARMACOTHERAPY OF SCHIZOPHRENIA 29
There a re se ve ra l ge ne ra l princi pl es to be kept in m ind whe n using thes e a gents.
With the excep t io n of c1ozap ine , m ost shou ld be co m bine d wi t h n euroleptics . They
s hou ld be introduced g rad ually, a nd side effects shou ld be monitored and treat ed
ea rly. Drugs s hou ld b e changed, one at a time if needed, after id e n tifying specific
target sym p tom s and monitoring changes carefu lly . Always d iscu ss the r isks and
benefit s with the patient a nd care fu lly document it in the chart (2,25) . Essentially,
these arc the principles of good pharma cotherapy.
Sch izo p h re nia, es pecia lly treatm ent resis ta n t illness, is hard to treat. Some
op t io ns for pharmacothe rapy d o ex is t. These op tions can be implemented log ica lly
a nd a re best d one a fte r id entifying specific target symptoms. Further research in this
a rea is clearly needed.
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